About soligenix - SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
SNGX At a Glance
Soligenix, Inc.
29 Emmons Drive
Princeton, New Jersey 08540-5919
| Phone | 1-609-538-8200 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -8,266,576.00 | |
| Sector | Health Technology | Employees | 16 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
SNGX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.646 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.195 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.798 |
SNGX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -516,661.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SNGX Liquidity
| Current Ratio | 1.80 |
| Quick Ratio | 1.80 |
| Cash Ratio | 1.613 |
SNGX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -88.112 |
| Return on Equity | -248.975 |
| Return on Total Capital | -147.543 |
| Return on Invested Capital | -212.966 |
SNGX Capital Structure
| Total Debt to Total Equity | 36.054 |
| Total Debt to Total Capital | 26.50 |
| Total Debt to Total Assets | 16.559 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |